Exploring the potential of ruthenium(ii)-phosphine-mercapto complexes as new anticancer agents

Author(s)

Palmeira-Mello, Marcos V. ; Costa, Analu R. ; de Oliveira, Leticia P. ; Blacque, Olivier ; Gasser, Gilles ; Batista, Alzir A.

• Document type: Journal article
• Source: DALTON TRANSACTIONS; v. 53, n. 26, p. 14-pg., 2024-06-19.

Abstract

The search for new metal-based anticancer drug candidates is a fundamental task in medicinal inorganic chemistry. In this work, we assessed the potential of two new Ru(ii)-phosphine-mercapto complexes as potential anticancer agents. The complexes, with the formula [Ru(bipy)(dppen)(Lx)]PF6 [(1), HL1 = 2-mercapto-pyridine and (2), HL2 = 2-mercapto-pyrimidine, bipy = 2,2 '-bipyridine, dppen = cis-1,2-bis(diphenylphosphino)-ethylene] were synthesized and characterized by nuclear magnetic resonance (NMR) [1H, 31P(1H), and 13C], high resolution mass spectrometry (HR-MS), cyclic voltammetry, infrared and UV-Vis spectroscopies. Complex 2 was obtained as a mixture of two isomers, 2a and 2b, respectively. The composition of these metal complexes was confirmed by elemental analysis and liquid chromatography-mass spectrometry (LC-MS). To obtain insights into their lipophilicity, their distribution coefficients between n-octanol/PBS were determined. Both complexes showed affinity mainly for the organic phase, presenting positive log P values. Also, their stability was confirmed over 48 h in different media (i.e., DMSO, PBS and cell culture medium) via HPLC, UV-Vis and 31P{1H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1, which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer. (AU)

• FAPESP's process: 22/09971-8 - Investigation of ruthenium(ii)-based complexes as chemotherapy anticancer candidates: from design to biological/biochemical studies
• Grantee: Marcos Vinícius Palmeira de Mello
• Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
• FAPESP's process: 23/02475-8 - Phosphine Ru(II) complexes with naphthoquinones and derivatives: potential anticancer, estudies in vitro and in vivo
• Grantee: Alzir Azevedo Batista
• Support Opportunities: Regular Research Grants
• FAPESP's process: 21/01787-0 - In vitro and in vivo study of Ru(II)/phosphine complexes with anticancer activities
• Grantee: Marcos Vinícius Palmeira de Mello
• Support Opportunities: Scholarships in Brazil - Post-Doctoral